TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39291303
Drug: Omalizumab-assisted multi-food
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Omalizumab-assisted multi-food oral immunotherapy (mOIT)
Study: 39291502
Drug: Guideline-directed optimal
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline-directed optimal medical therapy (receiving angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, β-blockers, and statins)
Study: 39291867
Drug: Model 2
Normalized name: Model 2004FAA Model 3-EEMK Model 3-EEMK-1 Model AA-8565 Model AA-8565-LATAM Model AWFAREMK Model CHAUTAUQUAEMK Model emk1000-10 Model FAREMK Model PMONTFAREMK Model SWEEMK Model SWEEMK-1 Model QXEMK Model G4FAREMK Model AA-8565 (excluding Miami Air) KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Model 2 (including 2 treatment-related predictors)
Study: 39291967
Drug: High-dose glucagon
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose glucagon
Study: 39292112
Drug: Electro-massage (ES)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electro-massage (ES) combined with Manual Therapy (MT)
Study: 39292433
Drug: Donanemab (13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donanemab (13 doses over 1 year)
Study: 39292927
Drug: Axatilimab 0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axatilimab 0.3 mg/kg every 2 weeks
Study: 39292927
Drug: Axatilimab 1
Normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axatilimab 1 mg/kg every 2 weeks
Study: 39292927
Drug: Axatilimab 3
Normalized name: Axatilimab
DrugBank: Axatilimab (DB16388)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Axatilimab 3 mg/kg every 4 weeks
Study: 39292928
Drug: Pomalidomide (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide (4 mg daily for 24 weeks)
Study: 39292975
Drug: Atezolizumab combined
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib
Study: 39293214
Drug: vYF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vYF vaccine (4, 5 or 6 Log CCID)
Study: 39293214
Drug: vYF vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: vYF vaccine
Study: 39293214
Drug: YF-VAX vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: YF-VAX vaccine
Study: 39293462
Drug: Open-label, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label, intravenous treatment (specific treatment not mentioned)
Study: 39293515
Drug: BMS-986365 (CC-94676)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986365 (CC-94676) at doses of 400-900 mg twice daily (n = 60)
Study: 39293515
Drug: BMS-986365 (CC-94676)
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BMS-986365 (CC-94676)
Study: 39293778
Drug: Progressive resistance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Progressive resistance training (RT) plus bone-loading exercises and placebo capsules
Study: 39293778
Drug: No RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: No RT and placebo capsules
Study: 39294149
Drug: BWC0977 (Novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: BWC0977 (Novel Bacterial Topoisomerase Inhibitor)
Study: 39294452
Drug: Polypharmacy (≥8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypharmacy (≥8 medications)
Study: 39294452
Drug: Potentially inappropriate
Normalized name: Potentilla discolor whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potentially inappropriate medications (≥1 PIM per STOPP)
Study: 39294522
Drug: Atomoxetine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine (10 or 18 mg)
Study: 39294797
Drug: Extracorporeal shock
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal shock wave (ESW) therapy
Study: 39296979
Drug: Prolgolimab 250
Normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolgolimab 250 mg Q3W
Study: 39296979
Drug: Prolgolimab 1
Normalized name: prolgolimab
DrugBank: Prolgolimab (DB16740)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolgolimab 1 mg/kg Q2W (historical control)
Study: 39297052
Drug: Rozanolixizumab 7
Normalized name: Rozanolixizumab
DrugBank: Rozanolixizumab (DB14919)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rozanolixizumab 7 mg/kg
Study: 39297691
Drug: PanBio indirect
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: PanBio indirect dengue virus immunoglobulin G (IgG) enzyme-linked immunosorbent assay (ELISA)
Study: 39297745
Drug: Calcineurin inhibitors
Normalized name: Calcineurin inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitors (Group A)
Study: 39297745
Drug: Mammalian target
Normalized name: Mammalian target of rapamycin (mTOR) kinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mammalian target of rapamycin inhibitors (sirolimus - Group B)
Study: 39297839
Drug: 14-day continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day continuous electrocardiogram patch monitor
Study: 39298147
Drug: Rogaratinib 600
Normalized name: Rogaratinib
DrugBank: Rogaratinib (DB15078)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rogaratinib 600 mg or 800 mg twice daily plus atezolizumab 1200 mg every 21 days
Study: 39298716
Drug: Palbociclib (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palbociclib (75 mg/m² orally once daily for 21 days of 28-day cycles)
Study: 39298718
Drug: Pembrolizumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab + Radiation Therapy (RT)
Study: 39299559
Drug: Simnotrelvir/ritonavir co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simnotrelvir/ritonavir co-administered with itraconazole (strong CYP3A and P-gp inhibitor)
Study: 39299559
Drug: Simnotrelvir/ritonavir co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simnotrelvir/ritonavir co-administered with midazolam (CYP3A substrate)
Study: 39299559
Drug: Simnotrelvir/ritonavir co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simnotrelvir/ritonavir co-administered with rifampicin (strong CYP3A and P-gp inducer)
Study: 39299734
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (OAC) started according to the '1-3-6-12 days rule' in 255 patients (39.2%).
Study: 39300008
Drug: Oxytocin maintenance
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin maintenance infusion at 4.5 IU·hr
Study: 39300008
Drug: 1-IU oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-IU oxytocin bolus followed by maintenance infusion
Study: 39300055
Drug: Calf Circumference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calf Circumference (CC)
Study: 39300055
Drug: BMI-adjusted CC
Approvals — FDA: no, EMA: no, PMDA: no
Description: BMI-adjusted CC
Study: 39300222
Drug: Ibrutinib 140
Normalized name: ibrutinib 140 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 140 mg/day
Study: 39300222
Drug: Ibrutinib 280
Normalized name: ibrutinib 280 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 280 mg/day
Study: 39300222
Drug: Ibrutinib 560
Normalized name: ibrutinib 560 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib 560 mg/day
Study: 39300222
Drug: Ibrutinib >560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib >560 mg/day
Study: 39300376
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (standard arm)
Study: 39300447
Drug: Ibrutinib (560
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (560 mg daily D3-14 and D17-28) in combination with R-MPV
Study: 39300447
Drug: Lenalidomide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenalidomide (15 mg daily D1-21) in combination with R-MPV
Study: 39300465
Drug: Standard national
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard national treatment of uncomplicated SAM
Study: 39300596
Drug: IV secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV secukinumab (6 mg/kg at baseline followed by 3 mg/kg every four weeks)
Study: 39300513
Drug: IV secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV secukinumab (3 mg/kg every four weeks after switching from placebo)
Study: 39300529
Drug: rTMS-active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS-active treatment for 10 consecutive days (n=10)
Study: 39300529
Drug: rTMS-sham treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS-sham treatment for 10 consecutive days (n=10)
Study: 39300529
Drug: rTMS-active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rTMS-active treatment
Study: 39300596
Drug: IV secukinumab
Normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV secukinumab (continued treatment through week 52)
Study: 39300870
Drug: Strengthening coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strengthening coping strategies and treatment expectations
Study: 39301110
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (20 µg)
Study: 39301110
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D insufficiency (<50 nmol/L)
Study: 39301223
Drug: Blended Trauma-focused
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended Trauma-focused Cognitive Therapy (bTF-CT)
Study: 39301485
Drug: 0.01% atropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01% atropine topical eye drop
Study: 39301593
Drug: Stepped care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stepped care including behavioural and antidepressant therapy (ADT)
Study: 39302614
Drug: SG 10
Normalized name: emapalumab-lzsg 10 MG in 2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SG 10 mg/kg
Study: 39302982
Drug: CBD-enriched Cannabis
Normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBD-enriched Cannabis Herbal Extract (MPL-001 with a THC:CBD of 1:25), starting at 0.2-0.4 mg/kg of CBD per day and escalating monthly up to 0.8-1.0 mg/kg of CBD per day
Study: 39303189
Drug: Radiotherapy (RT)
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radiotherapy (RT) with chemotherapy if node-positive
Study: 39303200
Drug: Nivolumab (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (240 mg once every 2 weeks for up to 12 doses)
Study: 39304237
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (20 mg/kg to a maximum of 1000 mg)
Study: 39304237
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate (200 mg; 65 mg elemental iron) three times daily until 6 weeks postpartum
Study: 39304241
Drug: Subcutaneous efgartigimod
Normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous efgartigimod PH20 (1000 mg weekly for a maximum of 48 weeks)
Study: 39304241
Drug: Subcutaneous efgartigimod
Normalized name: Efgartigimod alfa
DrugBank: Efgartigimod alfa (DB15270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous efgartigimod PH20
Study: 39304797
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen blockade (CAB) with goserelin (10.8 mg/3m) and bicalutamide (50 mg/OD)
Study: 39304797
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen blockade (CAB) with goserelin (10.8 mg/3m), bicalutamide (50 mg/OD), and dutasteride (0.5 mg/OD)
Study: 39304797
Drug: Combined androgen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined androgen blockade (CAB) with goserelin, bicalutamide, and dutasteride (0.5 mg/OD) in patients with disease progression after prior CAB therapy
Study: 39304918
Drug: standard in-person
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard in-person treatment as usual
Study: 39305031
Drug: Fast-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-acting insulin therapy
Study: 39305035
Drug: Individualised comprehensive
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised comprehensive physical therapy
Study: 39305160
Drug: vosoritide (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: vosoritide (15 μg/kg/day)
Study: 39305436
Drug: Atomoxetine (ato)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ato) 80 mg
Study: 39305436
Drug: Atomoxetine and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atomoxetine and spironolactone (ato-spiro) 80/50 mg
Study: 39305441
Drug: Relacorilant (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relacorilant (100-200 mg/day for up to 12 weeks or 250-400 mg/day for up to 16 weeks)
Study: 39305562
Drug: Cytokine release
Normalized name: cytosine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytokine release syndrome (CRS) treatment
Study: 39305562
Drug: Immune effector
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune effector cell-associated neurotoxicity syndrome (ICANS) treatment
Study: 39305910
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) followed by two cycles of 200 mg intravenous PD-1 inhibitor, tislelizumab, plus platinum-based chemotherapy.
Study: 39305913
Drug: Glucocorticoids in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids in combination with immunosuppressive agents or intravenous immunoglobulin
Study: 39306346
Drug: Apixaban at
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban at a reduced dose of 2.5 mg two times per day
Study: 39306346
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy adjusted to INR target (2-3)
Study: 39306350
Drug: First-line cessation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line cessation medications
Study: 39306468
Drug: Liver transplantation
Normalized name: LIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liver transplantation plus chemotherapy
Study: 39306585
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg i.v. every 2 weeks or every 3 weeks for ≤2 years
Study: 39306585
Drug: Ipilimumab 3
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 3 mg/kg i.v. every 3 weeks for four cycles
Study: 39306592
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement devices (MAD) treatment for OSA, two-piece adjustable appliances, standardized protocol, duration of six years.
Study: 39306592
Drug: Mandibular advancement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular advancement devices (MAD) treatment for OSA.
Study: 39306601
Drug: Modafinil 200
Normalized name: modafinil 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modafinil 200 mg twice daily
Study: 39306601
Drug: Amphetamine-dextroamphetamine 20
Normalized name: amphetamine-dextroamphetamine 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine-dextroamphetamine 20 mg twice daily
Study: 39306798
Drug: BQT (bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: BQT (bismuth quadruple therapy) - 14-day therapy with b.i.d. proton pump inhibitor 20 mg, bismuth 220 mg, tetracycline 400 mg q.i.d, metronidazole 400 mg q.i.d
Study: 39306798
Drug: PBMn (minocycline-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBMn (minocycline-containing therapy) - 14-day therapy with b.i.d. proton pump inhibitor 20 mg, minocycline 50 mg q.i.d, metronidazole 400 mg q.i.d
Study: 39306923
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg intravenously every three weeks
Study: 39307154
Drug: Memantine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine 20 mg once a day
Study: 39307154
Drug: Trazodone 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trazodone 200 mg once a day
Study: 39309703
Drug: AVATAR-based video
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVATAR-based video immersion with radiation therapy
Study: 39309726
Drug: Personalised remote
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised remote speech therapy for 8 weeks
Study: 39310045
Drug: CONNECTDROP® Medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: CONNECTDROP® Medication Event Monitoring System (MEMS) paired with a smartphone application
Study: 39310667
Drug: Higher-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-protein diet (HP; ∼38% of daily intake as protein)
Study: 39310667
Drug: Normal-protein diet
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal-protein diet (NP; ∼15% of daily intake as protein)
Study: 39310666
Drug: OC+P (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC+P (50 g prunes daily)
Study: 39310769
Drug: Bone marrow
Normalized name: bone marrow
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bone marrow aspirate concentrates (BMACs) from knee-OA patients; specific dosage and duration not mentioned.
Study: 39311597
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable cabotegravir (CAB-LA) 600 mg
Study: 39312625
Drug: Tactile massage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tactile massage (TM) for 15 minutes, twice a week for 4 weeks
Study: 39313288
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine
Study: 39313288
Drug: Escalated dose
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalated dose dCRT prescribed carboplatin/paclitaxel or cisplatin/capecitabine
Study: 39313594
Drug: Cetuximab (Cetux)
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab (Cetux) + chemotherapy
Study: 39313857
Drug: Inactivated COVID-19
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactivated COVID-19 vaccine (CoronaVac®) co-administered with inactivated enterovirus type 71 vaccine (Inlive®)
Study: 39314107
Drug: Pharmacologic agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic agents (e.g., botulinum toxin type A, injectable fillers, chemical peels)
Study: 39314125
Drug: Standard HepB3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard HepB3 vaccine series (group U3)
Study: 39315864
Drug: BRAF/MEK inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRAF/MEK inhibitors (encorafenib and binimetinib) followed by immune checkpoint inhibitors (ipilimumab and nivolumab)
Study: 39315864
Drug: Immune checkpoint
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune checkpoint inhibitors (ipilimumab and nivolumab) followed by BRAF/MEK inhibitors (encorafenib and binimetinib)
Study: 39315864
Drug: BRAF/MEK inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRAF/MEK inhibitors (encorafenib and binimetinib) for 8 weeks followed by immune checkpoint inhibitors (ipilimumab and nivolumab) and retreatment with BRAF/MEK inhibitors
Study: 39315892
Drug: RISA-PE stage
Approvals — FDA: no, EMA: no, PMDA: no
Description: RISA-PE stage B (A + serum lactate >2 mmol/L OR shock index ≥1)
Study: 39316400
Drug: Voice-activated, internet-delivered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice-activated, internet-delivered cognitive behavioral therapy for insomnia (CBT-I) program for 6 weeks
Study: 39316768
Drug: Decitabine and
Normalized name: Decitabine
DrugBank: Decitabine (DB01262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Decitabine and venetoclax (low-dose regimen)
Study: 39317492
Drug: SOC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC with early high-dose intravenous vitamin C (200 mg/kg per day, within 6 hours after return of spontaneous circulation, for 3 days)
Study: 39317492
Drug: SOC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SOC with early high-dose intravenous vitamin C
Study: 39317633
Drug: Niraparib 200
Normalized name: niraparib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib 200 mg and abiraterone acetate 1000 mg plus prednisone 10 mg (AAP)
Study: 39317994
Drug: Motor Interference
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Motor Interference Therapy (MIT)
Study: 39318595
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (discontinued empirical anti-MRSA therapy if nasal swab result is negative)
Study: 39318595
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (empirical treatment with linezolid or vancomycin)
Study: 39318719
Drug: Microbial inulinase
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Microbial inulinase supplementation (2000 inulinase activity units, twice daily for 4 weeks)
Study: 39318788
Drug: RMC-035 (1.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RMC-035 (1.3 or 0.65 mg/kg)
Study: 39319279
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg/day for patients weighing 10-20 kg (Group 1)
Study: 39319279
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg/day for patients weighing ≥20 kg (Group 2)
Study: 39319279
Drug: Esomeprazole 10
Normalized name: esomeprazole 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 10 mg/day for patients previously diagnosed with GU and/or DU (Group 3)